COP9 signalosome is an essential and druggable parasite target that regulates protein degradation
S. Ghosh, L. Farr, A. Singh, L.-A. Leaton, J. Padalia, D. Sullivan, S. Moonah
Abstract
Understanding how the protozoan protein degradation pathway is regulated could uncover new parasite biology for drug discovery. We found the COP9 signalosome (CSN) conserved in multiple pathogens such as Leishmania, Trypanosoma, Toxoplasma, and used the severe diarrhea-causing Entamoeba histolytica to study its function in medically significant protozoa. We show that CSN is an essential upstream regulator of parasite protein degradation. Genetic disruption of E. histolytica CSN by two distinct approaches inhibited cell proliferation and viability. Both CSN5 knockdown and dominant negative mutation trapped cullin in a neddylated state, disrupting UPS activity and protein degradation. In addition, zinc ditiocarb (ZnDTC), a main metabolite of the inexpensive FDA-approved alcohol-abuse drug disulfiram, was active against parasites acting in a COP9-dependent manner. ZnDTC, given as disulfiram-zinc, had oral efficacy in clearing parasites in vivo. Our findings provide insights into the regulation of parasite protein degradation, and supports the significant therapeutic potential of COP9 inhibition. Summary sentenceParasite-encoded COP9 signalosome is an essential upstream regulator of ubiquitin-proteasome mediated protein degradation, and shows significant potential as a therapeutic target.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Evaluation of Known Human PDE Inhibitors Against Nematode PDE4s
C. S. Anindya, C. S. Hoffman·bioRxiv·Feb 24, 2023
- Chemical degradation identified Human p38-MAPK as a host target to combat parasitic infections
Jhalak Singhal, Neha Rawat, … Shailja Singh·Communications BiologyPeer-reviewed·Jun 11, 2026
- Gene silencing in Cryptosporidium: A rapid approach to identify novel targets for drugdevelopment
A. Castellanos-Gonzalez, G. Martinez-Traverso, … A. C. White·bioRxiv·May 2, 2019
- A genome-scale drug discovery pipeline uncovers new therapeutic targets and a unique p97 allosteric binding site in Schistosoma mansoni
D.R. Stephens, Ho Yee Joyce Fung, … James J. Collins·Proceedings of the National Academy of SciencesPeer-reviewed·Aug 29, 2025
- From Proteome Mining to Structural Validation: Phosphopyruvate Hydratase as a Structurally Tractable Drug Target in Kinetoplastid Parasites
Luis Daniel Goyzueta-Mamani, Haruna Luz Barazorda-Ccahuana, … Miguel Á. Chávez‐Fumagalli·bioRxiv·Jun 12, 2026
- Most inhibitors with defined yeast targets have limited activity against the microsporidian Nematocida parisii
Qingyuan Huang, Guoqing Pan, … Aaron W Reinke·bioRxiv·Jun 10, 2026